APA (7th ed.) Citation

Salzmann, M., Wald, A., Stege, H., Loquai, C., Zimmer, L., Hayani, K. M., . . . Hassel, J. C. (2023). Tolerability of BRAF and MEK inhibitors for metastasized melanoma after intra-class switch: A multicenter, retrospective study. Cancers, 15(5), . https://doi.org/10.3390/cancers15051426

Chicago Style (17th ed.) Citation

Salzmann, Martin, et al. "Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma After Intra-class Switch: A Multicenter, Retrospective Study." Cancers 15, no. 5 (2023). https://doi.org/10.3390/cancers15051426.

MLA (9th ed.) Citation

Salzmann, Martin, et al. "Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma After Intra-class Switch: A Multicenter, Retrospective Study." Cancers, vol. 15, no. 5, 2023, https://doi.org/10.3390/cancers15051426.